All In Biotech

NDA 022407 · Theravance INC

Vibativ

Telavancin · Injection

Last checked: Nov 20, 2026Latest source record: Jun 21, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Jun 21, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

15

5 Phase 3, 1 recruiting

FAERS reports

120

91 serious, 12 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 21, 2013 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval ReviewMedication GuideLabel
2 products under this application
  • VIBATIV · TELAVANCIN 750MG · INJECTABLE, INJECTION · Prescription
  • VIBATIV · TELAVANCIN 250MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Telavancin" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use19
  • renal failure acute15
  • blood creatinine increased12
  • nausea12
  • chills9
  • thrombocytopenia7
  • diarrhoea6
  • dyspnoea6
  • leukopenia6
  • renal failure6
  • vomiting6
  • acute kidney injury5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20092
201033
201145
20125
20144
20161
201823
20194
20251
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vibativ (Telavancin HCl)

2024 spending

$553K

Beneficiaries

33

137 claims

Per beneficiary

$16,770

$33.54 per unit

View as table
YearSpending
2020$0
2021$628,663
2022$618,855
2023$781,599
2024$553,402

Part B: Vibativ (Telavancin HCL) · HCPCS J3095

2024 spending

$1.1M

Beneficiaries

138

1,362 claims

Per beneficiary

$7,729

2024 ASP limit $7.12 per unit

View as table
YearSpending
2020$1,871,453
2021$1,353,073
2022$1,223,977
2023$1,683,613
2024$1,066,665

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 47 on PubMed

Sponsor: Theravance INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.